Premium
The economic consequences of Alzheimer's disease in the context of new drug developments
Author(s) -
Knapp Martin,
Wilkinson David,
Wigglesworth Rachel
Publication year - 1998
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/(sici)1099-1166(199808)13:8<531::aid-gps815>3.0.co;2-m
Subject(s) - disease , drug class , medicine , drug , alzheimer's disease , context (archaeology) , cognition , intensive care medicine , psychiatry , psychology , gerontology , paleontology , pathology , biology
Abstract The first national symptomatic treatment for Alzheimer's disease has received a very mixed and perhaps ageist reception from purchasers of health care in the UK. This is largely because detailed information on the long‐term effects of this class of drugs is scarce. However, by looking at the published evidence on the economic burden of Alzheimer's disease, some observations and assumptions can be made as to the influence of the new drug treatments. The drug therapies available and those most likely to become licensed are reviewed and the potential economic impact is discussed. Long‐term outcome studies would properly address this, but as these drugs have now demonstrated efficacy, particularly in non‐cognitive behaviours, it will be ethically more difficult to maintain patients on placebo for long periods. Some assumptions therefore have to be made from long‐term open‐label studies. Those drugs currently available, and those in development, may offer effective treatment for some of the core symptoms of Alzheimer's disease, slowing the rate of cognitive decline and preserving competence in activities of daily living for longer. If handled correctly, these treatments have the potential to offer cost savings for many patients, and cost‐effectiveness improvements look probable. © 1998 John Wiley & Sons, Ltd.